|
ALG13 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62458935193399E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.22044604925031E-16 |
| Normal-vs-Stage2 |
4.21929999999682E-05 |
| Normal-vs-Stage3 |
3.84969833788773E-12 |
| Normal-vs-Stage4 |
1.62436730732907E-12 |
| Stage1-vs-Stage2 |
3.346500E-02 |
| Stage1-vs-Stage3 |
1.191210E-01 |
| Stage1-vs-Stage4 |
1.93706999999099E-05 |
| Stage2-vs-Stage3 |
1.045830E-02 |
| Stage2-vs-Stage4 |
3.18020000000807E-06 |
| Stage3-vs-Stage4 |
1.533960E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.44089209850063E-16 |
| Normal-vs-AfricanAmerican |
5.2791999660684E-09 |
| Normal-vs-Asian |
1.7120005413318E-10 |
| Caucasian-vs-AfricanAmerican |
2.189400E-01 |
| Caucasian-vs-Asian |
9.728400E-01 |
| AfricanAmerican-vs-Asian |
2.579000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
2.72326605710305E-12 |
| Male-vs-Female |
1.06730000393185E-08 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.626032641866E-12 |
| Normal-vs-Age(41-60Yrs) |
4.52859971744601E-13 |
| Normal-vs-Age(61-80Yrs) |
1.05849773390787E-11 |
| Normal-vs-Age(81-100Yrs) |
4.48149999999758E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.206800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.895000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.945600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.988000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.045400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.981000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.178600E-03 |
| Classical-VS-Follicular |
8.36140000000096E-05 |
| Classical-VS-Other |
5.854400E-02 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
1.44699999982123E-07 |
| Tall-VS-Other |
6.206200E-01 |
| Tall-VS-Normal |
1.72772907092167E-12 |
| Follicular-VS-Other |
1.770600E-04 |
| Follicular-VS-Normal |
1.029410E-04 |
| Other-VS-Normal |
1.04199999739762E-08 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.30115967684242E-12 |
| Normal-vs-N1 |
7.74209996112774E-09 |
| N0-vs-N1 |
5.903200E-01 |
|
|
